<DOC>
	<DOCNO>NCT00066794</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclosporine , daunorubicin , cytarabine , use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : This phase II trial study well give cyclosporine together daunorubicin cytarabine work treat old patient untreated acute myeloid leukemia .</brief_summary>
	<brief_title>S0301 Cyclosporine , Daunorubicin , Cytarabine Treating Older Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy cyclosporine , daunorubicin , cytarabine old patient previously untreated acute myeloid leukemia . - Determine frequency severity toxic effect regimen patient . - Determine , preliminarily , frequency prognostic significance functional phenotypic P-glycoprotein expression cytogenetics patient treat regimen . - Determine , preliminarily , pharmacokinetic characteristic regimen patient . OUTLINE : This multicenter study . - Induction therapy : Patients receive cyclosporine IV daunorubicin IV continuously day 1-3 cytarabine IV continuously day 1-7 . Patients achieve complete response ( CR ) chemotherapy receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) IV subcutaneously begin day 15 20 continue blood count recover . Patients maintain CR 2 course induction therapy proceed consolidation therapy . - Consolidation therapy : Patients receive treatment induction therapy cyclosporine daunorubicin day 1-2 cytarabine day 1-5 . Patients achieve CR receive additional course chemotherapy begin least 14 day completion first course cytarabine . Patients follow every 3 month 1 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 25-64 patient accrue study within 13 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute myeloid leukemia ( AML ) Differential diagnosis AML base FAB classification system M0M7 ( No M3 ) No blastic transformation chronic myelogenous leukemia Must currently register protocol SWOG9007 SWOGS9910 PATIENT CHARACTERISTICS : Age 56 Performance status Zubrod 03 ( patient 56 60 year age ) OR Zubrod 02 ( patient 61 70 year age ) OR Zubrod 01 ( patient 71 year age ) Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 2 time upper limit normal ( ULN ) unless elevate unconjugated hyperbilirubinemia secondary Gilbert 's syndrome hemolysis liver dysfunction AST and/or ALT great 4 time ULN Renal Creatinine great 1.5 time ULN AND/OR Creatinine clearance great 40 mL/min Cardiovascular Left ventricular function normal Ejection fraction least 50 % MUGA echocardiogram No unstable cardiac arrhythmia No unstable angina Other Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent pegfilgrastim Chemotherapy At least 30 day since prior lowdose cytarabine ( le 100 mg/m^2/day ) myelodysplastic syndrome recover Prior hydroxyurea control high cell count allow No prior systemic chemotherapy acute leukemia Concurrent singledose intrathecal chemotherapy allow Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
</DOC>